Literature DB >> 8591970

Serotonin selective reuptake inhibitors in child and adolescent psychopharmacology: a review of published experience.

C L DeVane1, F R Sallee.   

Abstract

BACKGROUND: This review summarizes the published clinical experience with the serotonin selective reuptake inhibitors (SSRIs) in children and adolescents.
METHOD: A computerized literature search was conducted using MEDLINE back to 1986 to retrieve all reports of SSRI use in children and adolescents. Additional hand searches were performed with key journals. All reports relating clinical experience of SSRIs in children or adolescents were collated according to primary diagnosis.
RESULTS: We found 3 double-blind, placebo-controlled clinical trials (65 patients), 16 open- label trials (322 Patients), and 23 case reports (41 patients) on the use of SSRIs in younger populations. The reports described clinical effects, mostly benefits, for 13 indications. A theoretical rationale exists for use of SSRIs in most conditions for which they are prescribed.
CONCLUSION: The most convincing evidence for efficacy for SSRIs in adolescents exists for treatment of depression and obsessive-compulsive disorder. Only sparse evidence, mostly anecdotal, exists for efficacy in other conditions. The reported side effects were modest, but behavioral disturbances in some cases limit recommendations and warrant caution for widespread use.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8591970

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  9 in total

Review 1.  A risk-benefit assessment of pharmacotherapies for clinical depression in children and adolescents.

Authors:  J Renaud; D Axelson; B Birmaher
Journal:  Drug Saf       Date:  1999-01       Impact factor: 5.606

2.  Changes in child and adolescent inpatient psychiatric admission diagnoses between 1995 and 2000.

Authors:  Ilan Harpaz-Rotem; Douglas L Leslie; Andres Martin; Robert A Rosenheck
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2005-08-18       Impact factor: 4.328

Review 3.  Selective serotonin re-uptake inhibitors for children and adolescents.

Authors:  C F Ziervogel
Journal:  Eur Child Adolesc Psychiatry       Date:  2000       Impact factor: 4.785

Review 4.  The selective serotonin reuptake inhibitor sertraline: its profile and use in psychiatric disorders.

Authors:  G MacQueen; L Born; M Steiner
Journal:  CNS Drug Rev       Date:  2001

Review 5.  Fluvoxamine: a review of its therapeutic potential in the management of anxiety disorders in children and adolescents.

Authors:  S M Cheer; D P Figgitt
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

Review 6.  Pharmacokinetic and pharmacodynamic drug interactions in the treatment of attention-deficit hyperactivity disorder.

Authors:  J S Markowitz; K S Patrick
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

7.  Fluoxetine in treatment of adolescent patients with autism: a longitudinal open trial.

Authors:  S H Fatemi; G M Realmuto; L Khan; P Thuras
Journal:  J Autism Dev Disord       Date:  1998-08

8.  Neurological and cardiovascular adverse events associated with antimanic treatment in children and adolescents.

Authors:  Jeanette M Jerrell
Journal:  CNS Neurosci Ther       Date:  2009-09-21       Impact factor: 5.243

9.  Changes in outpatient psychiatric diagnosis in privately insured children and adolescents from 1995 to 2000.

Authors:  Ilan Harpaz-Rotem; Robert A Rosenheck
Journal:  Child Psychiatry Hum Dev       Date:  2004
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.